Loading...
By Amy Orciari Herman
Edited by Susan Sadoughi, MD, and André Sofair, MD, MPH
Dipeptidyl peptidase-4 (DPP-4) inhibitors, used for glucose control in patients with type 2 diabetes, may cause severe and disabling joint pain, the FDA warned on Friday. Drugs in this class include sitagliptin, saxagliptin, linagliptin, and alogliptin.
A search of the FDA Adverse Event Reporting System database revealed 33 cases of severe arthralgia associated with DPP-4 inhibitors from 2006 (when the first was approved) through 2013. Ten patients required hospitalization for disabling pain. In most cases, symptoms began within a month after starting treatment, but the time to onset ranged from 1 day to years after drug initiation. Symptoms usually resolved by 1 month after treatment discontinuation.
When patients present with severe arthralgia, the FDA says, clinicians should evaluate DPP-4 inhibitors as a potential cause and consider stopping treatment. Providers should report such adverse events to the agency's MedWatch program (see link below).
Comment
LINK(S):
FDA MedWatch safety alert (Free)
FDA MedWatch reporting form (Free)
Background: Physician's First Watch coverage of prior troubles with DPP-4 inhibitors (Free)